NEW YORK, Aug. 30, 2017 -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced that Ben Taylor, President and Chief Financial Officer, will present at the following upcoming investor conferences:
Event: Landmark’s Investing for Cures Forum
Date: September 7, 2017
Time: 10:35 AM EDT
Location: New York, NY
Event: BioCentury Newsmakers in the Biotech Industry Conference
Date: September 8, 2017
Time: 2:30 PM EDT
Location: New York, NY
Event: Rodman & Renshaw 19th Annual Global Investment Conference
Date: September 11, 2017
Time: 9:10 AM EDT
Location: New York, NY
About Tyme
Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, our therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Our lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and we are preparing to initiate an additional Phase II clinical trial for pancreatic cancer. For more information, visit our website: www.tymeinc.com.
Contacts ICR Healthcare Media / Investors James Heins / Stephanie Carrington Tel: +1 203 682 8251 Tel: +1 646 277 1282 Email: James.Heins@icrinc.com Email: Stephanie.Carrington@icrinc.com
